• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    NovoCure Limited - Ordinary Shares (NQ: NVCR )

    31.90 +0.93 (+3.00%)
    Streaming Delayed Price Updated: 4:00 PM EST, Dec 26, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 694,441
    Open 30.73
    Bid (Size) 31.11 (1)
    Ask (Size) 32.00 (2)
    Prev. Close 30.97
    Today's Range 30.25 - 31.99
    52wk Range 11.70 - 34.13
    Shares Outstanding 103,647,871
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Walgreens Boots Alliance, Alaska Air And RH Are Among Top Mid-Cap Gainers Last Week (December 9-13): Are The Others In Your Portfolio?
    These 10 mid-cap stocks performed well last week. Are they in your portfolio? PDCO, NAMS, WBA, NVCR, RH, PTVE, CRK, RNW, ALK, STVN. 
    Via Benzinga
    SoundHound, Asana And Victorias Secret Are Among Top 10 Mid Cap Gainers Last Week (Dec 2-Dec 6): Are The Others In Your Portfolio?
    Top performing mid-cap stocks last week: NBIS, SOUN, BTDR, ASAN, JANX, NVCR, KC, VSCO, ZETA, FIVE. Analysts raise price forecasts for these stocks. 
    Via Benzinga

    Performance

    YTD
    +121.53%
    +121.53%
    1 Month
    +78.41%
    +78.41%
    3 Month
    +103.83%
    +103.83%
    6 Month
    +80.94%
    +80.94%
    1 Year
    +110.14%
    +110.14%

    More News

    Read More
    Why NovoCure Stock Was Winning Big This Week
    Via The Motley Fool
    Novocure Has Already Doubled in 2024. Can It Soar Higher in 2025?
    Via The Motley Fool
    12 Health Care Stocks Moving In Monday's Pre-Market Session
    Via Benzinga
    Novocure Launches 40% After Pancreatic Cancer Treatment Succeeds
    Via Investor's Business Daily
    Navigating 5 Analyst Ratings For NovoCure
    Via Benzinga
    Dow Dips 150 Points; ISM Manufacturing PMI Tops Estimates
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    XPeng, NovoCure, Merus, Gap And Other Big Stocks Moving Higher On Monday
    Via Benzinga
    NovoCure's Tumor-Treating Electric Fields Shows Promise In Pancreatic Cancer Patients
    Via Benzinga
    This Gap Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
    Via Benzinga
    Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer
    From Zai Lab
    Via Business Wire
    Deep Dive Into NovoCure Stock: Analyst Perspectives (4 Ratings)
    Via Benzinga
    Novocure Announces Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer
    From Novocure
    Via Business Wire
    Novocure to Participate in Upcoming Investor Conferences
    From Novocure
    Via Business Wire
    Novocure Data at 2024 SNO Annual Meeting Highlights Product Innovation and Real-World Evidence for Tumor Treating Fields (TTFields) Therapy in Glioblastoma
    From Novocure
    Via Business Wire
    FDA Approves Novocure’s Innovative HFE Transducer Arrays for Use With Optune Gio® for Glioblastoma
    From Novocure
    Via Business Wire
    NovoCure (NVCR) Q3 2024 Earnings Call Transcript
    Via The Motley Fool
    Topics Earnings
    Exposures Financial
    Novocure Appoints Christoph Brackmann as Chief Financial Officer
    From Novocure
    Via Business Wire
    Novocure Reports Third Quarter 2024 Financial Results
    From Novocure
    Via Business Wire
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session
    Via Benzinga
    US Stocks Could Open Narrowly Mixed After Tuesday's Chip Sell-Off, Bitcoin Heads To $68K, Oil Slips
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    FDA Approves NovoCure's Portable Device Producing Tumor-Treating Electric Fields For Previously Treated Lung Cancer Patients
    Via Benzinga
    Exposures Product Safety
    Novocure Shoots Skyward, Reversing Setbacks, After FDA Approves Lung Cancer Treatment
    Via Investor's Business Daily
    Exposures Product Safety
    FDA Approves Novocure’s Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer
    From Novocure
    Via Business Wire
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.